重组人干扰素α1b注射液联合利巴韦林治疗流行性腮腺炎患儿的疗效及安全性分析

Analysis of the Efficacy and Safety of Recombinant Human Interferonα1b Injection Combined with Ribavirin in the Treatment of Children with Mumps

目的:探讨重组人干扰素α1b注射液联合利巴韦林治疗流行性腮腺炎患儿的疗效及安全性。方法:选取2019年4月—2020年11月南阳市中医院87例流行性腮腺炎患儿作为研究对象,采用随机数表法分为对照组43例和观察组44例。对照组给予利巴韦林治疗,观察组在利巴韦林基础上给予重组人干扰素α1b注射液,均治疗5d。观察两组疗效、临床症状改善时间(退热时间、腮腺肿大缓解时间、腮腺肿痛缓解时间及尿淀粉酶恢复时间)、不良反应,对比治疗前后T淋巴细胞亚群水平(CD4^(+)/CD8^(+)、CD8^(+)、CD3^(+))、白细胞介素-6(IL-6)、可溶性白细胞-2受体(SIL-2R)水平。结果:观察组治疗总有效率高于对照组,差异有统计学意义(χ^(2)=7.572,P<0.05)。观察组腮腺肿大缓解时间、腮腺肿痛缓解时间及退热时间、尿淀粉酶恢复时间短于对照组,差异有统计学意义(t=12.791、11.340、13.155、12.601,P<0.05)。治疗后观察组CD3^(+)、CD4^(+)/CD8^(+)水平高于对照组,CD8^(+)水平低于对照组,差异有统计学意义(t=5.644、4.720、9.581,P<0.05)。治疗后观察组IL-6、SIL-2R水平低于对照组,差异有统计学意义(t=6.866、8.862,P<0.05)。观察组不良反应发生率与对照组比较,差异无统计学意义(χ^(2)=0.001,P>0.05)。结论:重组人干扰素α1b注射液联合利巴韦林用于流行性腮腺炎患儿,可调节T淋巴细胞亚群水平,减轻炎症反应,控制临床症状,提高治疗效果,且安全性较高。

Objective:To investigate the efficacy and safety of recombinant human interferonα1b injection combined with riba­virin in the treatment of children with mumps.Methods:87 cases of mumps children in the hospital from April 2019 to November 2020 were randomly divided into control group(n=43)and observation group(n=44)according to the random number table method.The control group was given ribavirin,and the observation group was given recombinant human interferon α 1b injection on the ba­sis of ribavirin,both groups were treated for 5 d.The curative effect,improvement time of clinical symptoms(antipyretic time,parotid gland swelling relief time,parotid gland swelling and pain relief time,urine amylase recovery time)and adverse reactions were ob­served.The levels of T lymphocyte subsets(CD4^(+)/CD8^(+),CD8^(+),CD3^(+)),interleukin-6(IL-6)and soluble interleukin-2 receptor(SIL-2R)were compared between the two groups before and after treatment.Results:The total effective rate of the observation group was higher than that of the control group(χ^(2)=7.572,P<0.05).The parotid gland swelling,swelling and pain relief time,fever relief time and urine amylase recovery time in the observation group were shorter than those in the control group,with statistically significant difference(t=12.791,11.340,13.155,12.601,P<0.05).After treatment,the levels of CD3^(+),CD4^(+)/CD8^(+)in the observa­tion group were higher than those in the control group,and the CD8^(+)level was lower than that in the control group,with statistical­ly significant difference(t=5.644,4.720,9.581,P<0.05).After treatment,the levels of IL-6 and SIL-2R in the observation group were lower than those in the control group,with statistically significant difference(t=6.866,8.862,P<0.05).There was no statisti­cally significant difference in the incidence of adverse reactions between the observation group and the control group(χ^(2)=0.001,P>0.05).Conclusion:Recombinant human interferon α 1b injection combined with ribavirin in children with mumps can regulate the level of T lymphocyte subsets,reduce inflammatory reaction,control clinical symptoms,improve the therapeutic effect,which has high safety.